A Phase 1 interventional study of CKD-846 and D091 in Benign Prostate Hypertrophy(BPH), sponsored by Chong Kun Dang Pharmaceutical. Completed at 1 site in South Korea. Open to male participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-21.
Sponsored by Chong Kun Dang Pharmaceutical · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 72 studies in Prostatic Hyperplasia with a site in Korea, Republic of — 6 open to participants now, 6 under way, none of them phase 3. Prostatic Hyperplasia · Korea, Republic of.
Among the 72 studies in Prostatic Hyperplasia with a site in Korea, Republic of, this one is the 46th largest by enrollment of the 57 interventional ones that give a count, is one of 7 that started in 2026, is one of 20 in phase 1, and was the 67th registered.
831 studies on the registry are indexed under Prostatic Hyperplasia; 181 are open to participants now.
Browse Prostatic Hyperplasia studies →6 of the 72 studies in Prostatic Hyperplasia with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Addpharma Inc. · Sites in Korea, Republic of
Ages 19+ · Men only · Healthy volunteers
Saint Vincent's Hospital, Korea · Sites in Korea, Republic of
Ages 50+ · Men only
Société Internationale d'Urologie · Sites in Korea, Republic of, United States, Canada and 18 more countries
Ages 18+ · Men only
AJU Pharm Co., Ltd. · Sites in Korea, Republic of
Ages 19–54 · Men only · Healthy volunteers
Addpharma Inc. · Sites in Korea, Republic of
Ages 19+ · Men only · Healthy volunteers
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.
This study: 19 Years to 55 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
72 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 34 is below the median of 94 across 629 interventional studies indexed under Prostatic Hyperplasia.
Median enrollment 83 across the 57 interventional studies, 300 across the 15 observational. Of the 54 that completed or were terminated, 8 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 72 have an industry lead sponsor. The 10 most frequent:
Chong Kun Dang Pharmaceutical is the lead sponsor of 299 studies on the registry; 14 are open to participants now.
Chong Kun Dang Pharmaceutical has 7 studies filed under Prostatic Hyperplasia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 72 studies in Prostatic Hyperplasia with a site in Korea, Republic of, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A Clinical trial to compare and evaluate evaluate the pharmacokinetics and safety of CKD-846
A randomized, open-label and parallel study to evaluate the pharmacokinetics and safety of CKD-846 in healthy male subjects
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CKD-846, Single dose
Drug: CKD-846
CKD-846, Single dose
Drug: CKD-846
CKD-846, Single dose
Drug: CKD-846
D091, Multi dose
Drug: D091
once administration of Investigational Product
once administration of Investigational Product
Plasma Concentration of D091
Concentration of During the administration period
Time frame: Pre-dose, Post-dose Day1~Day34 (During the administration period)
Plasma Concentration of CKD-846
Concentration of During the administration period
Time frame: Pre-dose, Post-dose Day1~Day91 (During the administration period)
Plan to share: No
No publications or documents are linked to this record.
Ran from Feb 2026 to primary completion in Jun 2026, 3 months.
Of 26 industry-sponsored phase 1 interventional studies under Prostatic Hyperplasia, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 4. This study's 3 months is close to that.
Counting every sponsor, half of 34 studies reached it within 3 months; a quarter within 1 and three quarters within 6.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chong Kun Dang Pharmaceutical →